Biomedicines (Apr 2022)

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma

  • Anne S. Boewe,
  • Silke Wemmert,
  • Philipp Kulas,
  • Bernhard Schick,
  • Claudia Götz,
  • Selina Wrublewsky,
  • Mathias Montenarh,
  • Michael D. Menger,
  • Matthias W. Laschke,
  • Emmanuel Ampofo

DOI
https://doi.org/10.3390/biomedicines10050966
Journal volume & issue
Vol. 10, no. 5
p. 966

Abstract

Read online

Juvenile angiofibroma (JA) is a rare fibrovascular neoplasm predominately found within the posterior nasal cavity of adolescent males. JA expresses the proteoglycan nerve–glial antigen (NG)2, which crucially determines the migratory capacity of distinct cancer cells. Moreover, it is known that the protein kinase CK2 regulates NG2 gene expression. Therefore, in the present study, we analyzed whether the inhibition of CK2 suppresses NG2-dependent JA cell proliferation and migration. For this purpose, we assessed the expression of NG2 and CK2 in patient-derived JA tissue samples, as well as in patient-derived JA cell cultures by Western blot, immunohistochemistry, flow cytometry and quantitative real-time PCR. The mitochondrial activity, proliferation and migratory capacity of the JA cells were determined by water-soluble tetrazolium (WST)-1, 5-bromo-2′-deoxyuridine (BrdU) and collagen sprouting assays. We found that NG2 and CK2 were expressed in both the JA tissue samples and cell cultures. The treatment of the JA cells with the two CK2 inhibitors, CX-4945 and SGC-CK2-1, significantly reduced NG2 gene and protein expression when compared to the vehicle-treated cells. In addition, the loss of CK2 activity suppressed the JA cell proliferation and migration. These findings indicate that the inhibition of CK2 may represent a promising therapeutic approach for the treatment of NG2-expressing JA.

Keywords